The current vaccine regime against influenza is protective, which usually includes 2 strains of type A and 1 strain of type B capable of producing strong antibody responses to the surface glycoprotein hemagglutinin (HA) and neuraminidase (NA) of these viruses. This evidence concerns the gene XK and influenza.